Paxlovid gets a bad rap over concerns about Covid “rebound.” That’s the primary takeaway from a series of papers showing that whether or not people take the antiviral medication, many have symptoms that wax and wane before going away completely.
The studies aim to address concerns over a phenomenon called Paxlovid rebound, which occurs when someone who has taken an antiviral such as Paxlovid experiences a resurgence in symptoms or a positive test after testing negative soon after they stop taking the drug. One of the first papers to describe COVID resurgence after an antiviral was a case study co-authored by Davey Smith, an infectious disease physician and researcher at the University of California, San Diego, and his colleagues.
In one of the studies, published in JAMA Network Open last October, Smith and his colleagues looked at a group of placebo-group subjects in the ACTIV-2 trial and found that 30 percent experienced at least two symptom-free days before one or more of their symptoms returned. Of those who had this symptom rebound, almost all had symptoms that were mild to moderate and none required hospitalization.
Robert Wachter, chair of the department of medicine at the University of California, San Francisco, has heard similar reactions to Paxlovid. “I’ve heard many times from patients and from a fair number of physicians that ‘I don’t like to use it because of rebound,’” he says. “I kind of understand it viscerally, but it doesn’t make sense when looking at a dispassionate ledger sheet of the medication’s benefits and downsides.... It’s not that close a call.
پاکستان تازہ ترین خبریں, پاکستان عنوانات
Similar News:آپ اس سے ملتی جلتی خبریں بھی پڑھ سکتے ہیں جو ہم نے دوسرے خبروں کے ذرائع سے جمع کی ہیں۔
ذریعہ: 24NewsHD - 🏆 19. / 51 مزید پڑھ »
ذریعہ: 24NewsHD - 🏆 19. / 51 مزید پڑھ »
ذریعہ: 24NewsHD - 🏆 19. / 51 مزید پڑھ »
ذریعہ: 24NewsHD - 🏆 19. / 51 مزید پڑھ »
ذریعہ: 92newschannel - 🏆 21. / 51 مزید پڑھ »
ذریعہ: 24NewsHD - 🏆 19. / 51 مزید پڑھ »